The 2018 EHRA* practical guide on non–vitamin K antagonist oral anticoagulants (NOACs) in patients with atrial fibrillation (AF) walks clinicians through 20 topics of clinical scenarios, including stroke management, NOAC use in conditions other than AF, and when to measure plasma levels. [Eur Heart J 2018; doi.org/10.1093/eurheartj/ehy136]
Real-world studies on patients with atrial fibrillation (AF) show that dabigatran is safe with low bleeding and stroke rates when used for long term (over 2 years) or used continuously in patients undergoing cardiovascular (CV) interventions, according to phase II results of the prospective, observational, global registry programme GLORIA-AF* presented at the EHRA 2018 Annual Congress.
An algorithm to help stratify patients with syncope requiring hospitalization vs those that can be discharged from the emergency department (ED) safely forms part of the new European Society Cardiology (ESC) syncope guidelines launched at the EHRA 2018 meeting.
Continuous apixaban seems equally safe as warfarin and other vitamin K antagonists (VKAs) during atrial fibrillation (AF) ablation in patients at risk for stroke, according to the AXAFA–AFNET* 5 trial presented at EHRA 2018.
Asia's trusted medical magazine for healthcare professionals.
Get your MIMS Doctor - Malaysia digital copy today!
Not only does the CGRP* inhibitor galcanezumab show sustained efficacy in migraine patients, long-term treatment does not come with excess cardiovascular (CV) risk, according to studies presented at the AAN 2021 Annual Meeting.
Migraine and headache are common ailments of people living in the modern era. Dr Jon Marshall of The Singapore Headache and Migraine Clinic shares his insights with Pearl Toh on how to manage migraine and headache using non-pharmaceutical strategies, with a focus on the manual medicine approach.
Among atrial fibrillation (AF) patients with clinically defined heart failure, catheter ablation yields greater survival gains, freedom from AF recurrence, and quality of life boost than does drug therapy, according to the results of the CABANA AF* substudy.
Combination treatment with three or more antihypertensive drugs provides greater blood pressure (BP)-lowering effect than monotherapy, results of a study have shown. However, the net benefit may be lessened when side effects are considered.